AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
trovafloxacin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibacterials, nalidixic acid derivatives | 2777 | 147059-72-1 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 0.20 | g | O |
| 0.20 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Hosey CM, Chan R, Benet LZ |
| BA (Bioavailability) | 91 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Vd (Volume of distribution) | 1.30 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 1.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.24 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 11 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 26 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | GRK2,PDK1,PDK2,PDK4 | 4 | |||
| kinase-selectivity-class | AXL,CDK9,DYRK1B,EIF2AK3,GRK2,MAP2K6,MAPK7,PRKDC | 8 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Dec. 18, 1997 | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01MA13 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE QUINOLONE ANTIBACTERIALS Fluoroquinolones |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D059003 | Topoisomerase Inhibitors |
| MeSH PA | D059005 | Topoisomerase II Inhibitors |
| CHEBI has role | CHEBI:33281 | antimicrobial agent |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:50908 | hepatotoxic agent |
| CHEBI has role | CHEBI:53559 | topoisomerase IV inhibitor |
| CHEBI has role | CHEBI:59517 | DNA synthesis inhibitor |
Related Drugs by ATC class:
J01MA Fluoroquinolones 22 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Infection due to Pseudomonas aeruginosa | indication | 11218009 | |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Acute gonococcal cervicitis | indication | 20943002 | DOID:10615 |
| Staphylococcal pneumonia | indication | 22754005 | |
| Acute gonococcal urethritis | indication | 29864006 | |
| Acute bacterial peritonitis | indication | 31860008 | |
| Postoperative infection | indication | 33910007 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Pneumonia due to Pseudomonas | indication | 41381004 | |
| Gonorrhea of rectum | indication | 42746002 | |
| Pneumonia due to Mycoplasma pneumoniae | indication | 46970008 | |
| Pneumonia due to Escherichia coli | indication | 51530003 | |
| Acute gonococcal endometritis | indication | 65295003 | DOID:7527 |
| Miscarriage with sepsis | indication | 67465009 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Acute bacterial sinusitis | indication | 75498004 | |
| Endomyometritis | indication | 88027004 | |
| Female genital tract infection | indication | 125585007 | |
| Infectious disease of abdomen | indication | 128070006 | |
| Postnatal infection | indication | 178280004 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Chlamydial pelvic inflammatory disease | indication | 188463006 | |
| Acute Moraxella catarrhalis bronchitis | indication | 195722003 | |
| Acute bacterial bronchitis | indication | 233598009 | |
| Chlamydial pneumonia | indication | 233609002 | |
| Female pelvic cellulitis | indication | 280486004 | |
| Streptococcal Septic Abortion | indication | ||
| Complicated Klebsiella Peritonitis | indication | ||
| Complicated E. Coli Peritonitis | indication | ||
| Enterococcus Endomyometritis | indication | ||
| Complicated Streptococcus Peritonitis | indication | ||
| Complicated Skin and Skin Structure Pseudomonas Aeruginosa Infection | indication | ||
| Complicated Bacteroides Peritonitis | indication | ||
| Prevotella Postpartum Infection | indication | ||
| Gardnerella Endomyometritis | indication | ||
| Gardnerella Postpartum Infection | indication | ||
| Peptostreptococcus Pelvic Cellulitis | indication | ||
| Prevotella Septic Abortion | indication | ||
| Bacteroides Septic Abortion | indication | ||
| E. Coli Endomyometritis | indication | ||
| Colorectal Surgery Infection Prevention | indication | ||
| Vaginal Hysterectomy Infection Prevention | indication | ||
| Pelvic Inflammatory Disease with Neisseria Gonorrhea | indication | ||
| Chronic Bacterial Prostatitis | indication | ||
| Haemophilus Parainfluenzae Bronchitis | indication | ||
| Haemophilus Influenzae Bronchitis | indication | ||
| Streptococcus Pneumoniae Bronchitis | indication | ||
| Staphylococcus Aureus Bronchitis | indication | ||
| Chlamydia Cervicitis | indication | ||
| Complicated Skin and Skin Structure Enterococcus Faecalis Infection | indication | ||
| Moraxella Catarrhalis Pneumonia | indication | ||
| Streptococcal Endomyometritis | indication | ||
| Peptostreptococcus Postpartum Infection | indication | ||
| Legionella Pneumophila Pneumonia | indication | ||
| Peptostreptococcus Septic Abortion | indication | ||
| Streptococcal Postpartum Infection | indication | ||
| E. Coli Pelvic Cellulitis | indication | ||
| E. Coli Postpartum Infection | indication | ||
| Enterococcus Postpartum Infection | indication | ||
| E. Coli Septic Abortion | indication | ||
| Peptostreptococcus Endomyometritis | indication | ||
| Gardnerella Septic Abortion | indication | ||
| Prevotella Endomyometritis | indication | ||
| Complicated Bacterial Peritonitis | indication | ||
| Complicated Skin and Skin Structure Staphylococcus Aureus Infection | indication | ||
| Prevotella Pelvic Cellulitis | indication | ||
| Streptococcal Pelvic Cellulitis | indication | ||
| Bacteroides Postpartum Infection | indication | ||
| Gardnerella Pelvic Cellulitis | indication | ||
| Enterococcus Pelvic Cellulitis | indication | ||
| Complicated Skin and Skin Structure Proteus Infection | indication | ||
| Enterococcus Septic Abortion | indication | ||
| Complicated Skin and Skin Structure E. Coli Infection | indication | ||
| Bacteroides Pelvic Cellulitis | indication | ||
| Bacteroides Endomyometritis | indication | ||
| Complicated Skin and Skin Structure Streptococcus Agalactiae Infection | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 5.92 | acidic |
| pKa2 | 8.56 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium-dependent dopamine transporter | Transporter | Ki | 4.31 | DRUG MATRIX | |||||
| Thromboxane-A synthase | Enzyme | IC50 | 5.40 | DRUG MATRIX | |||||
| Topoisomerase IV | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| DNA gyrase | Enzyme | INHIBITOR | CHEMBL | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4024108 | VUID |
| N0000022113 | NUI |
| D02123 | KEGG_DRUG |
| 4021091 | VANDF |
| 4024108 | VANDF |
| C0379881 | UMLSCUI |
| CHEBI:9763 | CHEBI |
| TR6 | PDB_CHEM_ID |
| CHEMBL428 | ChEMBL_ID |
| CHEMBL1200779 | ChEMBL_ID |
| DB00685 | DRUGBANK_ID |
| C080163 | MESH_SUPPLEMENTAL_RECORD_UI |
| 62959 | PUBCHEM_CID |
| 13476 | IUPHAR_LIGAND_ID |
| 7370 | INN_ID |
| 147059-75-4 | SECONDARY_CAS_RN |
| 9F388J00UK | UNII |
| 115552 | RXNORM |
| 5646 | MMSL |
| 7888 | MMSL |
| d04263 | MMSL |
| 007320 | NDDF |
| 007321 | NDDF |
| 116542007 | SNOMEDCT_US |
| 371322001 | SNOMEDCT_US |
| 96092008 | SNOMEDCT_US |
Pharmaceutical products:
None